{"id":988160,"date":"2026-08-01T15:14:08","date_gmt":"2026-08-01T19:14:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investors-have-opportunity-to-lead-capricor-therapeutics-inc-securities-fraud-lawsuit-with-sbs-law\/"},"modified":"2026-08-01T15:14:08","modified_gmt":"2026-08-01T19:14:08","slug":"capr-investors-have-opportunity-to-lead-capricor-therapeutics-inc-securities-fraud-lawsuit-with-sbs-law","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investors-have-opportunity-to-lead-capricor-therapeutics-inc-securities-fraud-lawsuit-with-sbs-law\/","title":{"rendered":"CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law"},"content":{"rendered":"

<\/p>\n

CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law <\/b><\/p>\n

LOS ANGELES–(BUSINESS WIRE<\/a>)–Schall, Brown & Schwartz LLP<\/a> (\u201cSBS\u201d), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. (\u201cCapricor\u201d or \u201cthe Company\u201d) (NASDAQ: CAPR<\/a>) for violations of \u00a7\u00a710(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.<\/p>\n

\nShareholders who purchased shares of CAPR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.<\/p>\n

CLASS PERIOD:<\/b> December 17, 2025 to July 26, 2026<\/p>\n

DEADLINE: <\/b>September 28, 2026<\/p>\n

\nIf you are a shareholder who suffered a loss, click here to participate<\/a>.<\/p>\n

CASE DETAILS: <\/b>According to the Complaint, the Company made false and misleading statements to the market. Capricor changed the statistical analysis plan used to analyze the clinical data related to Deramiocel despite the fact that the FDA had not agreed to changes from the pre-specified plan before the resubmission of its Biologics License Application (\u201cBLA\u201d). The Company faced a significant risk the FDA would not approve the BLA for Deramiocel based on a lack of sufficient evidence of effectiveness. Based on these facts, the Company\u2019s public statements were false and materially misleading throughout the class period. When the market learned the truth about Capricor, investors suffered damages.<\/p>\n

\nWe also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com<\/a>, or by email at david@schallfirm.com<\/a>.<\/p>\n

\nThe class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.<\/p>\n

Join the case<\/a> to recover your losses<\/p>\n

WHY SBS?<\/b> Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.<\/p>\n

\nThis press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260801160021\/en\/<\/a><\/span><\/p>\n

\nSchall, Brown & Schwartz LLP
\n
Brian Schall, Esq.,
\n
Andrew Brown, Esq.,
\n
David Schwartz, Esq.,
\n
www.schallfirm.com
\n<\/a>
Office: 310-301-3335
\n
info@schallfirm.com<\/a><\/p>\n

KEYWORDS:<\/b> California United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Class Action Lawsuit Professional Services Legal<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law LOS ANGELES–(BUSINESS WIRE)–Schall, Brown & Schwartz LLP (\u201cSBS\u201d), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. (\u201cCapricor\u201d or \u201cthe Company\u201d) (NASDAQ: CAPR) for violations of \u00a7\u00a710(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of CAPR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery. CLASS PERIOD: December 17, 2025 to July 26, 2026 DEADLINE: September 28, 2026 If you … <\/p>\n

Continue reading “CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-988160","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investors-have-opportunity-to-lead-capricor-therapeutics-inc-securities-fraud-lawsuit-with-sbs-law\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law LOS ANGELES–(BUSINESS WIRE)–Schall, Brown & Schwartz LLP (\u201cSBS\u201d), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. (\u201cCapricor\u201d or \u201cthe Company\u201d) (NASDAQ: CAPR) for violations of \u00a7\u00a710(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of CAPR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery. CLASS PERIOD: December 17, 2025 to July 26, 2026 DEADLINE: September 28, 2026 If you … Continue reading "CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investors-have-opportunity-to-lead-capricor-therapeutics-inc-securities-fraud-lawsuit-with-sbs-law\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-01T19:14:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260801160021r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-investors-have-opportunity-to-lead-capricor-therapeutics-inc-securities-fraud-lawsuit-with-sbs-law\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-investors-have-opportunity-to-lead-capricor-therapeutics-inc-securities-fraud-lawsuit-with-sbs-law\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law\",\"datePublished\":\"2026-08-01T19:14:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-investors-have-opportunity-to-lead-capricor-therapeutics-inc-securities-fraud-lawsuit-with-sbs-law\\\/\"},\"wordCount\":467,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-investors-have-opportunity-to-lead-capricor-therapeutics-inc-securities-fraud-lawsuit-with-sbs-law\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260801160021r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-investors-have-opportunity-to-lead-capricor-therapeutics-inc-securities-fraud-lawsuit-with-sbs-law\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-investors-have-opportunity-to-lead-capricor-therapeutics-inc-securities-fraud-lawsuit-with-sbs-law\\\/\",\"name\":\"CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-investors-have-opportunity-to-lead-capricor-therapeutics-inc-securities-fraud-lawsuit-with-sbs-law\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-investors-have-opportunity-to-lead-capricor-therapeutics-inc-securities-fraud-lawsuit-with-sbs-law\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260801160021r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2026-08-01T19:14:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-investors-have-opportunity-to-lead-capricor-therapeutics-inc-securities-fraud-lawsuit-with-sbs-law\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-investors-have-opportunity-to-lead-capricor-therapeutics-inc-securities-fraud-lawsuit-with-sbs-law\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-investors-have-opportunity-to-lead-capricor-therapeutics-inc-securities-fraud-lawsuit-with-sbs-law\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260801160021r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260801160021r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-investors-have-opportunity-to-lead-capricor-therapeutics-inc-securities-fraud-lawsuit-with-sbs-law\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investors-have-opportunity-to-lead-capricor-therapeutics-inc-securities-fraud-lawsuit-with-sbs-law\/","og_locale":"en_US","og_type":"article","og_title":"CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law - Market Newsdesk","og_description":"CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law LOS ANGELES–(BUSINESS WIRE)–Schall, Brown & Schwartz LLP (\u201cSBS\u201d), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. (\u201cCapricor\u201d or \u201cthe Company\u201d) (NASDAQ: CAPR) for violations of \u00a7\u00a710(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of CAPR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery. CLASS PERIOD: December 17, 2025 to July 26, 2026 DEADLINE: September 28, 2026 If you … Continue reading \"CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investors-have-opportunity-to-lead-capricor-therapeutics-inc-securities-fraud-lawsuit-with-sbs-law\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-01T19:14:08+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260801160021r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investors-have-opportunity-to-lead-capricor-therapeutics-inc-securities-fraud-lawsuit-with-sbs-law\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investors-have-opportunity-to-lead-capricor-therapeutics-inc-securities-fraud-lawsuit-with-sbs-law\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law","datePublished":"2026-08-01T19:14:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investors-have-opportunity-to-lead-capricor-therapeutics-inc-securities-fraud-lawsuit-with-sbs-law\/"},"wordCount":467,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investors-have-opportunity-to-lead-capricor-therapeutics-inc-securities-fraud-lawsuit-with-sbs-law\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260801160021r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investors-have-opportunity-to-lead-capricor-therapeutics-inc-securities-fraud-lawsuit-with-sbs-law\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investors-have-opportunity-to-lead-capricor-therapeutics-inc-securities-fraud-lawsuit-with-sbs-law\/","name":"CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investors-have-opportunity-to-lead-capricor-therapeutics-inc-securities-fraud-lawsuit-with-sbs-law\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investors-have-opportunity-to-lead-capricor-therapeutics-inc-securities-fraud-lawsuit-with-sbs-law\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260801160021r1&sid=flmnd&distro=nx&lang=en","datePublished":"2026-08-01T19:14:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investors-have-opportunity-to-lead-capricor-therapeutics-inc-securities-fraud-lawsuit-with-sbs-law\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/capr-investors-have-opportunity-to-lead-capricor-therapeutics-inc-securities-fraud-lawsuit-with-sbs-law\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investors-have-opportunity-to-lead-capricor-therapeutics-inc-securities-fraud-lawsuit-with-sbs-law\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260801160021r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260801160021r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investors-have-opportunity-to-lead-capricor-therapeutics-inc-securities-fraud-lawsuit-with-sbs-law\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/988160","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=988160"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/988160\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=988160"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=988160"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=988160"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}